{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:15:12Z","timestamp":1768094112636,"version":"3.49.0"},"reference-count":14,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,12,29]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Relapsed\/refractory (R\/R) peripheral T cell lymphoma (PTCL) has a poor prognosis, with limited treatment options and generally no durable response. However, long-term remission with the histone deacetylase (HDAC) inhibitor romidepsin has been reported, especially in angioimmunoblastic T cell lymphoma (AITL). Recently, tucidinostat, a novel oral HDAC inhibitor that selectively inhibits class I and class IIb HDACs, was approved for R\/R PTCL in China and Japan. We present the case of a patient with AITL whose gastrointestinal symptoms and health-related quality of life improved after switching from romidepsin to tucidinostat as maintenance therapy. Romidepsin and tucidinostat appear to have different safety profiles; non-haematological toxicities such as nausea, vomiting, constipation, anorexia and fatigue may be reported less frequently with tucidinostat than with romidepsin. This case suggests that switching to tucidinostat therapy may be a viable option for patients with PTCL suffering from severe gastrointestinal adverse events with romidepsin.<\/jats:p>","DOI":"10.1136\/bcr-2023-256315","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T13:18:01Z","timestamp":1704892681000},"page":"e256315","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Improving gastrointestinal quality of life: romidepsin to tucidinostat in a case of angioimmunoblastic T cell lymphoma"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3080-2341","authenticated-orcid":false,"given":"Atsushi","family":"Isoda","sequence":"first","affiliation":[{"name":"Department of Hematology, Iryo Hojin Hoshi Iin, Maebashi, Japan"},{"name":"Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Terasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Kanaya","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2025082723330808000_17.1.e256315.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"2025082723330808000_17.1.e256315.2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"2025082723330808000_17.1.e256315.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"2025082723330808000_17.1.e256315.4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-018-3418-2","article-title":"Forodesine in patients with relapsed peripheral T cell lymphoma: a multicenter phase 1\/2 study","volume":"98","author":"Maruyama","year":"2019","journal-title":"Ann Hematol"},{"key":"2025082723330808000_17.1.e256315.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"2025082723330808000_17.1.e256315.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"2025082723330808000_17.1.e256315.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"2025082723330808000_17.1.e256315.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"2025082723330808000_17.1.e256315.9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"2025082723330808000_17.1.e256315.10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor Tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"key":"2025082723330808000_17.1.e256315.11","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"2025082723330808000_17.1.e256315.12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol Oncol"},{"key":"2025082723330808000_17.1.e256315.13","doi-asserted-by":"crossref","first-page":"875469","DOI":"10.3389\/fonc.2022.875469","article-title":"Chidamide maintenance therapy following induction therapy in patients with peripheral T-cell lymphoma who are ineligible for autologous stem cell transplantation: case series from China","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"2025082723330808000_17.1.e256315.14","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2286-1"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:33:17Z","timestamp":1756362797000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bcr-2023-256315"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256315","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}